Rosetta Genomics Announces Presence at ASCO 2013

PHILADELPHIA and REHOVOT, Israel, May 28, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company will have a significant presence at the upcoming American Society of Clinical Oncologists Annual Meeting (ASCO 2013) taking place at the McCormick Convention Center in Chicago from May 31-June 4, 2013. 

Rosetta Genomics' Cancer Testing Services will be highlighted in an "Industry Expert Theater Presentation," which is a series of hour-long presentations from industry leaders sharing the latest in oncology practices, products, services and technologies*.  Kenneth A. Berlin, Rosetta Genomics' President and Chief Executive Officer, and E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics' Chief Medical Officer, will deliver a presentation entitled, "Application of microRNAs in Oncology Diagnostics," on Saturday, June 1st at 3:00 p.m. in the Oncology Professionals Hall. During this presentation, Dr. Wassman will showcase the Rosetta Cancer Origin Test^™ (formally miRview^® mets²) featuring case studies of patients with Cancer of Unknown or Uncertain Primary (CUP) impacted by test results, and data from extensive validation studies utilizing samples from real CUP patients, which demonstrated a high level of concordance with the predictions made by leading CUP centers.  

"I am excited to have the opportunity to reinforce the fact that, for physicians, patients, and their families, a diagnosis of Cancer of Unknown Primary in many cases is no longer acceptable. It is not a matter of whether to use microRNA profiling, but when to use it," added Dr. Wassman.

The Company will be featuring its Cancer Testing Services (formally known as the miRview^® product line) at Exhibit Booth 2101 beginning Saturday, June 1st from 9:00 a.m. through Monday, June 3rd at 5:00 PM Central Time.   Rosetta Genomics will have several company representatives, including medical staff, available to discuss its Cancer Testing Services. 

The Company's on-line abstract entitled, "Observational study of real world clinical performance of microRNA molecular profiling for cancer of unknown primary (CUP)," will be available for discussion at Rosetta's Exhibit Booth.  The study demonstrated a high level of concordance of the Rosetta Cancer Origin Test^™ with the clinical and/or pathological best final diagnosis.  There was strong agreement in over 85% of cases, and clinical utility, as measured by consideration of a shift in therapy or significantly increased decisional certainty for therapy, was observed in approximately 70% of the cases.  These data demonstrate that the Rosetta Cancer Origin Test^™ can make a meaningful difference to clinicians' management of their CUP patients.

"We are delighted to have such a strong presence at ASCO 2013, as it allows us to feature our potentially life-saving cancer diagnostic assays at this premier clinical and scientific meeting for oncologists.  We are excited to be hosting our first Exhibit Booth at ASCO 2013 and are particularly pleased to have our Cancer Testing Services featured in an Industry Expert Theater Presentation.  These are milestone achievements for Rosetta," stated Mr. Berlin. 

About Rosetta Cancer Testing Services (formerly the miRview^® product line)
Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test^™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test^™ diagnoses mesothelioma, a cancer connected to asbestos exposure.  The Rosetta Lung Cancer Test^™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test^™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.  Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test^™, 60,000 from the Rosetta Mesothelioma Test^™, 65,000 from the Rosetta Kidney Cancer Test^™ and 226,000 patients from the Rosetta Lung Cancer Test^™. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 1309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test, improving the ability of physicians to accurately diagnose CUP, the growth in number of samples being processed and billed at Rosetta's CLIA lab, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Rosetta Cancer Origin Test™, Rosetta's capitalization of its microRNA platform, Rosetta's patent position and Rosetta's development of personalized medicine products and services constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:                                                   
Rosetta Genomics                                          
Ken Berlin, President & CEO                                   
(215) 382-9000, ext. 1326                                         
[email protected]

Investor Contacts:                            
LHA                                       
Anne Marie Fields
(212) 838-3777
[email protected]
or
Bruce Voss
(310) 691-7100
[email protected]

SOURCE Rosetta Genomics Ltd.